Results 81 to 90 of about 50,140 (235)
Emerging therapeutic options for sporadic inclusion body myositis
, 2015 Lindsay N Alfano, Linda P Lowes Nationwide Children’s Hospital, Center for Gene Therapy, Columbus, OH, USA Abstract: Sporadic inclusion body myositis is the most common inflammatory muscle disorder preferentially affecting males over the age of ...
Lowes LP, Alfano LN
core
Arthritis &Rheumatology, EarlyView.Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo +23 more
wiley +1 more source
Recurrent Orbital Myositis: A Case Report
, 2007 Nonspesific orbital inflammatory syndromes (orbital pseudotumor) are a heterogeneous group of conditions. Orbital myositis is a subtype of this group involving one or more orbital muscles. It is quite rare in children. Corticosteroids are the mainstay of
Eda Ayberkin +4 more
core
New Spontaneous Model of Fibrodysplasia Ossificans Progressiva [PDF]
, 2008 We report the first known example of spontaneous, naturally occurring fibrodysplasia ossificans progressiva (FOP) in a mammal. The Southeast Asian mouse deer of the genus _Tragulus_ (Artiodactyla: Tragulidae) have an osseous sheath covering the lower ...
Robert Timm +2 more
core
Expert Perspective: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies
Arthritis &Rheumatology, Accepted Article.Treat‐to‐target (T2T) has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal T2T framework for adult IIM has not yet been established.
Shiri Keret +2 more
wiley +1 more source
Frontiers in ImmunologyImmune checkpoint inhibitors (ICIs) have been revolutionary in the field of cancer therapeutics. Myositis is a known rheumatic immunotherapy related adverse event with a fatality rate of 26.8% when associated with myasthenia gravis and 51.3% when ...
Monika A. Satoskar +6 more
doaj +1 more source
JRSM Open, 2019 Objective Myositis ossificans is a rare non-neoplastic form of heterotopic ossification most commonly described after trauma or surgery, in the diabetic foot. Design We provide a review of the literature including three illustrative cases.
Vivek Sharma +3 more
doaj +1 more source
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review
Frontiers in ImmunologyRuxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential ...
Xu Jing, Wang Min, Liu Xia, Li Shanshan
doaj +1 more source